Early prediction of immune checkpoint inhibitor treatment efficacy in patients with untreated advanced non-small-cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1011200014

Enrollment

Registered

2020-12-10

Start date

2020-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

18F-FDG PET/CT and liquid biopsy are performed 6 week after initiation of therapy with pembrolizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Previously untreated with chemotherapy 2. Patients more than 20 years old 3. Treated with pembrolizumab (combined with or without chemotherapy) 4. Appropriate physical status 5. Obtained informed consent

Exclusion criteria

Exclusion criteria: 1. Small-cell carcinoma or unknown 2. Positive for EGFR mutation, ALK fusion, Ros-1 fusion, and BRAF mutation 3. Ever treated with chemotherapy or radiotherapy 4. Poor physical status 5. Severe complication 6. Fasting blood glucose over 150 mg/dl 7. Unable to perform 18F-FDG PET/CT or CT because of complications 8. Other inappropriate patients

Design outcomes

Primary

Measure	Time frame
To evaluate the discriminative power of the change of SUVmax, which is obtained via PET/CT 6 week after the initiation of pembrolizumab treatment.	—

Secondary

Measure	Time frame
same analysis using liquid biopsy.	—

Contacts

Public ContactSatoshi Takeuchi

Hokkaido University Graduate School of Medicine

stakeuch@med.hokudai.ac.jp+81-11-706-5551

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026